NASDAQ:OCUP Ocuphire Pharma (OCUP) Stock Price, News & Analysis → Big Tech is spending billions each month on Nvidia’s AI superproject (From Weiss Ratings) (Ad) Free OCUP Stock Alerts $1.72 0.00 (0.00%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$1.71▼$1.7650-Day Range$1.51▼$2.0152-Week Range$1.50▼$4.58Volume108,933 shsAverage Volume196,423 shsMarket Capitalization$44.58 millionP/E RatioN/ADividend YieldN/APrice Target$18.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Ocuphire Pharma alerts: Email Address Ocuphire Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside990.1% Upside$18.75 Price TargetShort InterestHealthy4.82% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingAcquiring Shares$80,260 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.16) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.84 out of 5 starsMedical Sector381st out of 913 stocksPharmaceutical Preparations Industry176th out of 429 stocks 3.6 Analyst's Opinion Consensus RatingOcuphire Pharma has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOcuphire Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Ocuphire Pharma's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.82% of the outstanding shares of Ocuphire Pharma have been sold short.Short Interest Ratio / Days to CoverOcuphire Pharma has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Ocuphire Pharma has recently decreased by 5.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOcuphire Pharma does not currently pay a dividend.Dividend GrowthOcuphire Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCUP. Previous Next 2.2 News and Social Media Coverage News SentimentOcuphire Pharma has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ocuphire Pharma this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for OCUP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ocuphire Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocuphire Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $80,260.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.70% of the stock of Ocuphire Pharma is held by insiders.Percentage Held by InstitutionsOnly 14.97% of the stock of Ocuphire Pharma is held by institutions.Read more about Ocuphire Pharma's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ocuphire Pharma are expected to grow in the coming year, from ($1.16) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocuphire Pharma is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocuphire Pharma is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcuphire Pharma has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ocuphire Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsBig Tech is spending billions each month on Nvidia’s AI superprojectA small handful of Nvidia’s partners could see their own stocks surge upwards. They’re virtually unknown right now, but that won’t be the case much longer.Click here to find out who they are today. About Ocuphire Pharma Stock (NASDAQ:OCUP)Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.Read More OCUP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCUP Stock News HeadlinesJune 6, 2024 | globenewswire.comOcuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in JuneMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Ocuphire Pharma’s APX3330 Shows Promise for Diabetic Retinopathy and Pipeline ProgressMay 12, 2024 | finance.yahoo.comOcuphire Pharma First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | investorplace.comOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024May 10, 2024 | globenewswire.comOcuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 6, 2024 | globenewswire.comOcuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual MeetingMay 3, 2024 | globenewswire.comOcuphire Pharma to Present at the Aegis Virtual ConferenceApril 24, 2024 | finance.yahoo.comOcuphire Pharma, Inc. (OCUP)April 22, 2024 | globenewswire.comOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual MeetingApril 11, 2024 | globenewswire.comFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive SurgeryApril 1, 2024 | markets.businessinsider.comOcuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner ViatrisApril 1, 2024 | globenewswire.comOcuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner ViatrisMarch 27, 2024 | investing.comOcuphire Pharma COO acquires $4.1k in company stockMarch 15, 2024 | investorplace.comOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023March 13, 2024 | finance.yahoo.comEarnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their ForecastsMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy TreatmentMarch 10, 2024 | finance.yahoo.comOcuphire Pharma Full Year 2023 Earnings: Misses ExpectationsMarch 8, 2024 | globenewswire.comOcuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate UpdateMarch 4, 2024 | msn.comOcuphire (OCUP) to Report Q4 Earnings: What's in the Cards?February 26, 2024 | investorplace.com7 Under-the-Radar Biotech Stocks Gearing Up for LiftoffFebruary 23, 2024 | globenewswire.comOcuphire Pharma to Present in the BIO CEO & Investor ConferenceFebruary 15, 2024 | globenewswire.comOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 15, 2024 | uk.investing.comOcuphire Pharma Inc (OCUP)February 14, 2024 | finance.yahoo.comOcuphire Pharma Strengthens Leadership Team with Key AppointmentsFebruary 14, 2024 | globenewswire.comOcuphire Pharma Strengthens Leadership Team with Key AppointmentsSee More Headlines Receive OCUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocuphire Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/12/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OCUP CUSIPN/A CIK1228627 Webwww.ocuphire.com Phone(248) 681-9815Fax240-268-5310Employees14Year FoundedN/APrice Target and Rating Average Stock Price Target$18.75 High Stock Price Target$20.00 Low Stock Price Target$17.00 Potential Upside/Downside+980.6%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,990,000.00 Net Margins-59.44% Pretax Margin-59.38% Return on Equity-24.57% Return on Assets-22.22% Debt Debt-to-Equity RatioN/A Current Ratio8.96 Quick Ratio8.96 Sales & Book Value Annual Sales$19.05 million Price / Sales2.36 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / Book0.79Miscellaneous Outstanding Shares25,920,000Free Float23,669,000Market Cap$44.97 million OptionableOptionable Beta0.35 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Richard J. Rodgers M.B.A. (Age 57)Interim President & Director Comp: $62kMr. Bernhard Hoffmann M.B.A. (Age 68)Senior Vice President of Corporate Development & Operations and Secretary Comp: $348.96kMs. Amy Zaremba Rabourn C.P.A. (Age 43)MAcc, Senior Vice President of Finance Comp: $384.52kMr. George Magrath M.B.A.M.D., M.S., CEO & DirectorMr. Nirav Suresh Jhaveri C.F.A.Chief Financial OfficerMr. Joseph K. Schachle MBA (Age 59)Chief Operating Officer Dr. Ashwath Jayagopal Ph.D.Chief Scientific & Development OfficerDr. Daniela C. Oniciu Ph.D.Global Head of R&D, Chemistry and Product DevelopmentDr. Mitchell Brigell Ph.D.Head of Clinical Development & StrategyMr. Chris ErnstGlobal Head of QA & ManufacturingMore ExecutivesKey CompetitorsCapricor TherapeuticsNASDAQ:CAPRInventivaNASDAQ:IVALifecore BiomedicalNASDAQ:LFCRPuma BiotechnologyNASDAQ:PBYIOrganigramNASDAQ:OGIView All CompetitorsInsiders & InstitutionsAshwath JayagopalBought 3,500 shares on 5/22/2024Total: $6,160.00 ($1.76/share)Virtu Financial LLCBought 17,752 shares on 5/20/2024Ownership: 0.068%Vanguard Group Inc.Bought 64,400 shares on 5/10/2024Ownership: 3.874%Richmond Brothers Inc.Sold 25,308 shares on 5/10/2024Ownership: 0.888%Empowered Funds LLCBought 36,605 shares on 5/7/2024Ownership: 0.143%View All Insider TransactionsView All Institutional Transactions OCUP Stock Analysis - Frequently Asked Questions Should I buy or sell Ocuphire Pharma stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocuphire Pharma in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCUP shares. View OCUP analyst ratings or view top-rated stocks. What is Ocuphire Pharma's stock price target for 2024? 5 Wall Street analysts have issued 1-year target prices for Ocuphire Pharma's stock. Their OCUP share price targets range from $17.00 to $20.00. On average, they expect the company's share price to reach $18.75 in the next year. This suggests a possible upside of 990.1% from the stock's current price. View analysts price targets for OCUP or view top-rated stocks among Wall Street analysts. How have OCUP shares performed in 2024? Ocuphire Pharma's stock was trading at $3.01 at the beginning of 2024. Since then, OCUP stock has decreased by 42.9% and is now trading at $1.72. View the best growth stocks for 2024 here. When is Ocuphire Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our OCUP earnings forecast. How were Ocuphire Pharma's earnings last quarter? Ocuphire Pharma, Inc. (NASDAQ:OCUP) released its quarterly earnings results on Friday, May, 10th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.11. The firm had revenue of $1.71 million for the quarter, compared to analyst estimates of $3.01 million. Ocuphire Pharma had a negative trailing twelve-month return on equity of 24.57% and a negative net margin of 59.44%. Who are Ocuphire Pharma's major shareholders? Ocuphire Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.87%), Rice Hall James & Associates LLC (1.18%), Richmond Brothers Inc. (0.89%), Empowered Funds LLC (0.14%), Virtu Financial LLC (0.07%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ashwath Jayagopal, George Magrath, James S J Manuso, Jay Pepose, Joseph K Schachle, Mina Sooch and Nirav S Jhaveri. View institutional ownership trends. How do I buy shares of Ocuphire Pharma? Shares of OCUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCUP) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredI tried to warn you America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story o...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocuphire Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.